A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.

Details

Language :

English

ISSN :

09188959

Volume :

67

Issue :

8

Database :

Complementary Index

Journal :

Endocrine Journal

Publication Type :

Academic Journal

Accession number :

145396524

Full Text :

https://doi.org/10.1507/endocrj.ej19-0617